Zobrazeno 1 - 10
of 232
pro vyhledávání: '"C, Mautalen"'
Publikováno v:
Clinical Nephrology. 59:471-474
The efficacy and safety of the vitamin D analog, doxercalciferol (1alpha-hydroxyvitamin D2, 1alphaD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report these effect of 16-week 1alphaD2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4908248984db36b2df2ea903e4bfa998
https://doi.org/10.5414/cnp59471
https://doi.org/10.5414/cnp59471
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Salvatore Minisola, David L. Kendler, C. Mautalen, S Jensen, C J F Lin, M. L. Brandi, Rachel B. Wagman, Nadia Daizadeh, C. Roux, Jacques Reginster, A. Wang, M Gavin, P. Lakatos, Edward Franek, Kurt Lippuner, Socrates E. Papapoulos, Henry G. Bone, E.M. Lewiecki, Edward Czerwiński
Publikováno v:
Annals of the Rheumatic Diseases. 73:761.2-761
Background Denosumab (DMAb) is an approved therapy for the treatment of postmenopausal women with osteoporosis at increased risk for fracture. The effects of DMAb treatment for up to 10 years are being evaluated in the 3-year FREEDOM study and its 7-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb6c08cc5cebba04382e45a9a547a54d
https://doi.org/10.1136/annrheumdis-2014-eular.1119
https://doi.org/10.1136/annrheumdis-2014-eular.1119
Autor:
Y.-C. Yang, M. A. Bolognese, Jamie N. Brown, C. Recknor, M. Austin, Andreas Grauer, Stefan Goemaere, C. Mautalen, Klaus Engelke, Cesar Libanati, Harry K. Genant
Publikováno v:
Annals of the Rheumatic Diseases. 73:172.1-172
Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. Romosozumab, a monoclonal antibody to sclerostin, stimulates bone formation and decreases bone resorption. In a phase 2 study, romosozumab administered for 12 months incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5259d15e013b978a509dcb3b345f6eb5
https://doi.org/10.1136/annrheumdis-2014-eular.2526
https://doi.org/10.1136/annrheumdis-2014-eular.2526
Publikováno v:
Revue du rhumatisme (English ed.). 66(10)
A 27-year-old woman with anorexia nervosa since adolescence was referred to our unit for generalized bone pain most severe at the pelvis and an inability to stand. She reported a pelvic fracture diagnosed one year earlier, which had failed to heal. L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c7bfa8bc2bb64ca5edde6749e016660
https://pubmed.ncbi.nlm.nih.gov/10567980
https://pubmed.ncbi.nlm.nih.gov/10567980
Autor:
E, Smecuol, D, Gonzalez, C, Mautalen, A, Siccardi, M, Cataldi, S, Niveloni, R, Mazure, H, Vazquez, S, Pedreira, G, Soifer, L A, Boerr, E, Mauriño, J C, Bai
Publikováno v:
The American journal of gastroenterology. 92(4)
This prospective study was designed to assess the nutritional changes associated with the long-term treatment of celiac disease. In addition, we analyzed whether these changes were related to the degree of compliance with a gluten-free diet.We studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d9b9f59835dd6cb6822313b1a7cd8423
https://pubmed.ncbi.nlm.nih.gov/9128314
https://pubmed.ncbi.nlm.nih.gov/9128314
Autor:
C, Mautalen, D, González, R, Mazure, H, Vázquez, M P, Lorenzetti, E, Maurino, S, Niveloni, S, Pedreira, E, Smecuol, L A, Boerr, J C, Bai
Publikováno v:
The American journal of gastroenterology. 92(2)
Osteopenia is a common complication of celiac disease. The aims of this study were to evaluate whether treatment produces bone remineralization and whether calcium and vitamin D supplementation are necessary to reduce osteopenia.Bone mineral density
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::19beca51ee5df1661e2e49d07d1db98c
https://pubmed.ncbi.nlm.nih.gov/9040213
https://pubmed.ncbi.nlm.nih.gov/9040213
Publikováno v:
Medicina. 57
Bisphosphonates are the treatment of choice in patients with Paget's disease. However in patients with an extensive disease it has been difficult to achieve complete biochemical remission. We studied the efficacy of the new bisphosphonate: olpadronat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fdce954c41ed3271d89e511ac50cf525
https://pubmed.ncbi.nlm.nih.gov/9567351
https://pubmed.ncbi.nlm.nih.gov/9567351
Autor:
Nadia Daizadeh, A. Wang, S Jensen, E.M. Lewiecki, P. Lakatos, C. Zapalowski, Salvatore Minisola, Henry G. Bone, David L. Kendler, Rachel B. Wagman, C. Roux, C. Mautalen, Edward Franek, Steven Boonen, Kurt Lippuner
Publikováno v:
Annals of the Rheumatic Diseases. 72:A137.2-A137
Background Denosumab (DMAb) has been shown to decrease the risk for new vertebral, nonvertebral, and hip fractures in the 3-year FREEDOM trial. The FREEDOM open-label extension is evaluating the long-term effects of DMAb treatment for up to 10 years.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::968c09e72cda5bb286659395145036b1
https://doi.org/10.1136/annrheumdis-2013-eular.455
https://doi.org/10.1136/annrheumdis-2013-eular.455
Publikováno v:
The Journal of rheumatology. 23(12)
An 8-year-old girl with juvenile dermatomyositis (DM) developed dystrophic calcifications 26 months after diagnosis. She also had severe steroid induced bone loss (osteoporosis). The calcifications turned into generalized heterotopic calcinosis with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fdbd630ff7bc8f8c159755a21dc98724
https://pubmed.ncbi.nlm.nih.gov/8970055
https://pubmed.ncbi.nlm.nih.gov/8970055